Literature DB >> 32045236

2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes.

Sanjay Bhattarai1, Jan Pippel2, Emma Scaletti2, Riham Idris1, Marianne Freundlieb1, Georg Rolshoven1, Christian Renn1, Sang-Yong Lee1, Aliaa Abdelrahman1, Herbert Zimmermann3, Ali El-Tayeb1, Christa E Müller1, Norbert Sträter2.   

Abstract

CD73 inhibitors are promising drugs for the (immuno)therapy of cancer. Here, we present the synthesis, structure-activity relationships, and cocrystal structures of novel derivatives of the competitive CD73 inhibitor α,β-methylene-ADP (AOPCP) substituted in the 2-position. Small polar or lipophilic residues increased potency, 2-iodo- and 2-chloro-adenosine-5'-O-[(phosphonomethyl)phosphonic acid] (15, 16) being the most potent inhibitors with Ki values toward human CD73 of 3-6 nM. Subject to the size and nature of the 2-substituent, variable binding modes were observed by X-ray crystallography. Depending on the binding mode, large species differences were found, e.g., 2-piperazinyl-AOPCP (21) was >12-fold less potent against rat CD73 compared to human CD73. This study shows that high CD73 inhibitory potency can be achieved by simply introducing a small substituent into the 2-position of AOPCP without the necessity of additional bulky N6-substituents. Moreover, it provides valuable insights into the binding modes of competitive CD73 inhibitors, representing an excellent basis for drug development.

Entities:  

Year:  2020        PMID: 32045236     DOI: 10.1021/acs.jmedchem.9b01611

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Structure-Activity Relationship of 3-Methylcytidine-5'-α,β-methylenediphosphates as CD73 Inhibitors.

Authors:  Mirko Scortichini; Riham Mohammed Idris; Susanne Moschütz; Antje Keim; Veronica Salmaso; Clemens Dobelmann; Paola Oliva; Karolina Losenkova; Heikki Irjala; Samuli Vaittinen; Jouko Sandholm; Gennady G Yegutkin; Norbert Sträter; Anna Junker; Christa E Müller; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2022-01-26       Impact factor: 7.446

Review 2.  Expanding the repertoire of methanocarba nucleosides from purinergic signaling to diverse targets.

Authors:  Kenneth A Jacobson; Veronica Salmaso; R Rama Suresh; Dilip K Tosh
Journal:  RSC Med Chem       Date:  2021-07-13

Review 3.  Overview of Biologically Active Nucleoside Phosphonates.

Authors:  Elisabetta Groaz; Steven De Jonghe
Journal:  Front Chem       Date:  2021-01-08       Impact factor: 5.221

Review 4.  Ectonucleoside triphosphate diphosphohydrolases and ecto-5'-nucleotidase in purinergic signaling: how the field developed and where we are now.

Authors:  Herbert Zimmermann
Journal:  Purinergic Signal       Date:  2020-12-17       Impact factor: 3.765

5.  CD39 and CD73 as Promising Therapeutic Targets: What Could Be the Limitations?

Authors:  Ana Maria Oliveira Battastini; Fabricio Figueiró; Daniela Bitencourt Rosa Leal; Pedro Henrique Doleski; Maria Rosa Chitolina Schetinger
Journal:  Front Pharmacol       Date:  2021-03-11       Impact factor: 5.810

6.  CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer.

Authors:  Nataliia Petruk; Sanni Tuominen; Malin Åkerfelt; Jesse Mattsson; Jouko Sandholm; Matthias Nees; Gennady G Yegutkin; Arja Jukkola; Johanna Tuomela; Katri S Selander
Journal:  Sci Rep       Date:  2021-03-16       Impact factor: 4.379

7.  Substrate binding modes of purine and pyrimidine nucleotides to human ecto-5'-nucleotidase (CD73) and inhibition by their bisphosphonic acid derivatives.

Authors:  Emma Scaletti; Franziska U Huschmann; Uwe Mueller; Manfred S Weiss; Norbert Sträter
Journal:  Purinergic Signal       Date:  2021-08-17       Impact factor: 3.765

8.  Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity.

Authors:  Odd L Gammelgaard; Mikkel G Terp; Christian Renn; Aran F Labrijn; Oliver Hamaker; Aaraby Y Nielsen; Henriette Vever; Soren Wk Hansen; Morten F Gjerstorff; Christa E Müller; Paul Whi Parren; Henrik J Ditzel
Journal:  J Immunother Cancer       Date:  2022-09       Impact factor: 12.469

Review 9.  The elegant complexity of mammalian ecto-5'-nucleotidase (CD73).

Authors:  Karel P Alcedo; Jessica L Bowser; Natasha T Snider
Journal:  Trends Cell Biol       Date:  2021-06-08       Impact factor: 21.167

10.  Structure-activity relationships of pyrimidine nucleotides containing a 5'-α,β-methylene diphosphonate at the P2Y6 receptor.

Authors:  Paola Oliva; Mirko Scortichini; Clemens Dobelmann; Shanu Jain; Varun Gopinatth; Kiran S Toti; Ngan B Phung; Anna Junker; Kenneth A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2021-05-26       Impact factor: 2.940

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.